Dementia Alzheimer’s Research Papers ~January 2000

Dementia Alzheimer’s Research Papers ~January 2000    

     

           

Ott BR, Lapane KL, Gambassi G. Gender differences in the treatment of behavior problems in Alzheimer's disease. SAGE Study Group. Systemic Assessment of Geriatric drug use via Epidemiology. Neurology. 2000 Jan 25;54(2):427-32.

Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology. 2000 Jan 25;54(2):421-6.

Moceri VM, Kukull WA, Emanuel I, van Belle G, Larson EB. Early-life risk factors and the development of Alzheimer's disease. Neurology. 2000 Jan 25;54(2):415-20.

Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000 Jan 25;54(2):407-11.

Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M, Schoos B, Sabbagh MN, Masliah E, Thal LJ. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology. 2000 Jan 25;54(2):403-6.

  

Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000 Jan 25;54(2):295-301.

Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, Pfefferbaum A, Sullivan EV, Yesavage J, Alstiel L, Gasser T, Farlow MR, Murphy GM, Paul SM. Alpha2 macroglobulin and the risk of Alzheimer's disease. Neurology. 2000 Jan 25;54(2):438-42. , ,

Sogawa CA, Miyazaki I, Sogawa N, Asanuma M, Ogawa N, Furuta H. Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g). Brain Res. 2000 Jan 24;853(2):310-6.

Ray I, Chauhan A, Wegiel J, Chauhan VP. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 2000 Jan 24;853(2):344-51.

Scheper W, Zwart R, Sluijs P, Annaert W, Gool WA, Baas F. Alzheimer's presenilin 1 is a putative membrane receptor for rab GDP dissociation inhibitor. Hum Mol Genet. 2000 Jan 22;9(2):303-10.

Bergsdorf C, Paliga K, Kreger S, Masters CL, Beyreuther K. Identification of cis-elements regulating exon 15 splicing of the amyloid precursor protein pre-mRNA. J Biol Chem. 2000 Jan 21;275(3):2046-56.

Octave JN, Essalmani R, Tasiaux B, Menager J, Czech C, Mercken L. The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease. J Biol Chem. 2000 Jan 21;275(3):1525-8.

Kuner P, Bohrmann B, Tjernberg LO, Näslund J, Huber G, Celenk S, Grüninger-Leitch F, Richards JG, Jakob-Roetne R, Kemp JA, Nordstedt C. Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands. J Biol Chem. 2000 Jan 21;275(3):1673-8.

Ferrer I, Marín C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in patients with frontotemporal dementia. Neurosci Lett. 2000 Jan 21;279(1):33-6.

Weiss C, Preston AR, Oh MM, Schwarz RD, Welty D, Disterhoft JF. The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons. J Neurosci. 2000 Jan 15;20(2):783-90.

Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci. 2000 Jan 15;20(2):542-9.

Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J. 2000 Jan 15;345 Pt 2:263-70.

Hillen T, Lun A, Reischies FM, Borchelt M, Steinhagen-Thiessen E, Schaub RT. DHEA-S plasma levels and incidence of Alzheimer's disease. Biol Psychiatry. 2000 Jan 15;47(2):161-3.

Suzuki T, Nishiyama K, Yamamoto A, Inazawa J, Iwaki T, Yamada T, Kanazawa I, Sakaki Y. Molecular cloning of a novel apoptosis-related gene, human Nap1 (NCKAP1), and its possible relation to Alzheimer disease. Genomics. 2000 Jan 15;63(2):246-54.

  

Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000 Jan 15;20(2):558-67.

Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000 Jan 14;278(3):169-72. ,

Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 2000 Jan 11;54(1):240-2. ,

Hall KS, Gao S, Unverzagt FW, Hendrie HC. Low education and childhood rural residence: risk for Alzheimer's disease in African Americans. Neurology. 2000 Jan 11;54(1):95-9.

Lippa CF, Schmidt ML, Nee LE, Bird T, Nochlin D, Hulette C, Mori H, Lee VM, Trojanowski JQ. AMY plaques in familial AD: comparison with sporadic Alzheimer's disease. Neurology. 2000 Jan 11;54(1):100-4.

Munoz DG, Feldman H. Causes of Alzheimer's disease. CMAJ. 2000 Jan 11;162(1):65-72.

Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 2000 Jan 10;852(2):274-8.

Bassant MH, Poindessous-Jazat F, Schmidt BH. Sustained effect of metrifonate on cerebral glucose metabolism after immunolesion of basal forebrain cholinergic neurons in rats. Eur J Pharmacol. 2000 Jan 10;387(2):151-62.

Burns A. Might olfactory dysfunction be a marker of early Alzheimer's disease? Lancet. 2000 Jan 8;355(9198):84-5.

Pavía J, Alberch J, Alvárez I, Toledano A, de Ceballos ML. Repeated intracerebroventricular administration of beta-amyloid(25-35) to rats decreases muscarinic receptors in cerebral cortex. Neurosci Lett. 2000 Jan 7;278(1-2):69-72.

Helisalmi S, Hiltunen M, Mannermaa A, Koivisto AM, Lehtovirta M, Alafuzoff I, Ryynänen M, Soininen H. Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? Neurosci Lett. 2000 Jan 7;278(1-2):65-8. ,

Bullido MJ, Aldudo J, Frank A, Coria F, Avila J, Valdivieso F. A polymorphism in the tau gene associated with risk for Alzheimer's disease. Neurosci Lett. 2000 Jan 7;278(1-2):49-52. ,

Johnsingh AA, Johnston JM, Merz G, Xu J, Kotula L, Jacobsen JS, Tezapsidis N. Altered binding of mutated presenilin with cytoskeleton-interacting proteins. FEBS Lett. 2000 Jan 7;465(1):53-8.

Horning MS, Blakemore LJ, Trombley PQ. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 2000 Jan 3;852(1):56-61.

Gursky O, Aleshkov S. Temperature-dependent beta-sheet formation in beta-amyloid Abeta(1-40) peptide in water: uncoupling beta-structure folding from aggregation. Biochim Biophys Acta. 2000 Jan 3;1476(1):93-102.

Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WS. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000 Jan 1;20(1):149-55.

Opazo C, Ruiz FH, Inestrosa NC. Amyloid-beta-peptide reduces copper(II) to copper(I) independent of its aggregation state. Biol Res. 2000;33(2):125-31.

de Toledo-Morrell L, Dickerson B, Sullivan MP, Spanovic C, Wilson R, Bennett DA. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer's disease. Hippocampus. 2000;10(2):136-42.

Giacobini E. Present and future of Alzheimer therapy. J Neural Transm Suppl. 2000;59:231-42.

Olivieri G, Brack C, Müller-Spahn F, Stähelin HB, Herrmann M, Renard P, Brockhaus M, Hock C. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem. 2000 Jan;74(1):231-6.

Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):1-8.

Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, Andreatta CP. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol. 2000 Jan-Feb;23(1):2-13.

Hamann SB, Monarch ES, Goldstein FC. Memory enhancement for emotional stimuli is impaired in early Alzheimer's disease. Neuropsychology. 2000 Jan;14(1):82-92.

Fama R, Sullivan EV, Shear PK, Cahn-Weiner DA, Marsh L, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A. Structural brain correlates of verbal and nonverbal fluency measures in Alzheimer's disease. Neuropsychology. 2000 Jan;14(1):29-40.

Greenfield JP, Gross RS, Gouras GK, Xu H. Cellular and molecular basis of beta-amyloid precursor protein metabolism. Front Biosci. 2000 Jan 1;5:D72-83.

Salib E, Tadros G, Ambrose A. Autopsy in elderly psychiatric inpatients: a retrospective review of autopsy findings of deceased elderly psychiatric inpatients in north Cheshire 1980-1996. Med Sci Law. 2000 Jan;40(1):20-7.

Silva A, Montague JR, Lopez TF, Mudd LM. Growth factor effects on survival and development of calbindin immunopositive cultured septal neurons. Brain Res Bull. 2000 Jan 1;51(1):35-42.

Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci. 2000 Jan;12(1):227-38.

Cornman CB, Lane MJ, Davis DR, Sanderson M. Alzheimer's disease in South Carolina, 1998. J S C Med Assoc. 2000 Jan;96(1):18-21.

Switzer RC. Application of silver degeneration stains for neurotoxicity testing. Toxicol Pathol. 2000 Jan-Feb;28(1):70-83.

Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol. 2000 Jan;7(1):51-63.

Lansbury PT, Kosik KS. Neurodegeneration: new clues on inclusions. Chem Biol. 2000 Jan;7(1):R9-R12.

Nowotny P, Gorski SM, Han SW, Philips K, Ray WJ, Nowotny V, Jones CJ, Clark RF, Cagan RL, Goate AM. Posttranslational modification and plasma membrane localization of the Drosophila melanogaster presenilin. Mol Cell Neurosci. 2000 Jan;15(1):88-98.

Yamaguchi F, Yamaguchi K, Tokuda M. Presenilin-1 protein specifically expressed in Leydig cells with its expression level increased during rat testis development. Int J Biochem Cell Biol. 2000 Jan;32(1):81-7.

Passani MB, Bacciottini L, Mannaioni PF, Blandina P. Central histaminergic system and cognition. Neurosci Biobehav Rev. 2000 Jan;24(1):107-13.

Clark LM, Bosworth HB, Welsh-Bohmer KA, Dawson DV, Siegler IC. Relation between informant-rated personality and clinician-rated depression in patients with memory disorders. Neuropsychiatry Neuropsychol Behav Neurol. 2000 Jan;13(1):39-47.

Wagle AC, Ho LW, Wagle SA, Berrios GE. Psychometric behaviour of BDI in Alzheimer's disease patients with depression. Int J Geriatr Psychiatry. 2000 Jan;15(1):63-9.

Hofman M, Seifritz E, Kräuchi K, Hock C, Hampel H, Neugebauer A, Müller-Spahn F. Alzheimer's disease, depression and normal ageing: merit of simple psychomotor and visuospatial tasks. Int J Geriatr Psychiatry. 2000 Jan;15(1):31-9.

Devi G, Ottman R, Tang MX, Marder K, Stern Y, Mayeux R. Familial aggregation of Alzheimer disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. Arch Neurol. 2000 Jan;57(1):72-7.

Bagli M, Papassotiropoulos A, Jessen F, Rao ML, Maier W, Heun R. Gene-gene interaction between interleukin-6 and alpha2-macroglobulin influences the risk for Alzheimer's disease. Ann Neurol. 2000 Jan;47(1):138-9.

Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol. 2000 Jan;47(1):93-100.

Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Bowman ED, Schisterman EF, Vena JE, Shields PG. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog. 2000 Jan;27(1):2-9.

Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. J Nucl Med. 2000 Jan;41(1):57-64.

Klegeris A, McGeer PL. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol. 2000 Jan;67(1):127-33.

Carr DB, Duchek J, Morris JC. Characteristics of motor vehicle crashes of drivers with dementia of the Alzheimer type. J Am Geriatr Soc. 2000 Jan;48(1):18-22.

Evans M, Ellis A, Watson D, Chowdhury T. Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Int J Geriatr Psychiatry. 2000 Jan;15(1):50-3.

Londos E, Passant U, Brun A, Gustafson L. Clinical Lewy body dementia and the impact of vascular components. Int J Geriatr Psychiatry. 2000 Jan;15(1):40-9.

  

Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000 Jan;156(1):15-20.

Sóti C, Csermely P. Molecular chaperones and the aging process. Biogerontology. 2000;1(3):225-33.

Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-37.

Liberski PP, Ironside J, McCardle L, Sherring A. Ultrastructural analysis of the florid plaque in variant Creutzfeldt-Jakob disease. Folia Neuropathol. 2000;38(4):167-70.

de Carvalho CV, Payão SL, Smith MA. DNA methylation, ageing and ribosomal genes activity. Biogerontology. 2000;1(4):357-61.

Finkel LH. Neuroengineering models of brain disease. Annu Rev Biomed Eng. 2000;2:577-606.

Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger G, Fuchs D. Hyperhomocysteinemia in dementia. J Neural Transm. 2000;107(12):1469-74.

Brusco LI, Márquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett. 2000;21(1):39-42.

Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz MO, Strotmann T, Heiss WD. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm. 2000;107(12):1457-68.

Kimura M, Matsushita S, Arai H, Matsui T, Yuzuriha T, Higuchi S. No evidence of association between apolipoprotein E gene regulatory region polymorphism and Alzheimer's disease in Japanese. J Neural Transm. 2000;107(12):1449-56.

Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S. Possible reverse transport of beta-amyloid peptide across the blood-brain barrier. Acta Neurochir Suppl. 2000;76:73-7.

Lenigk R, Lam E, Lai A, Wang H, Han Y, Carlier P, Renneberg R. Enzyme biosensor for studying therapeutics of Alzheimer's disease. Biosens Bioelectron. 2000;15(9-10):541-7.

Domen J. The role of apoptosis in regulating hematopoiesis and hematopoietic stem cells. Immunol Res. 2000;22(2-3):83-94.

Srebro Z, Wilinski B, Sura P. [Oxidative stress in Alzheimer's disease] Folia Med Cracov. 2000;41(3-4):165-70.

Strosznajder JB, J sko H, Strosznajder RP. Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochim Pol. 2000;47(3):847-54.

Buchet R, Pikula S. Alzheimer's disease: its origin at the membrane, evidence and questions. Acta Biochim Pol. 2000;47(3):725-33.

Ransmayr G. Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. J Neural Transm Suppl. 2000;(60):303-14.

Zheng WH, Kar S, Doré S, Quirion R. Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J Neural Transm Suppl. 2000;(60):261-72.

Belluardo N, Mudo G, Blum M, Amato G, Fuxe K. Neurotrophic effects of central nicotinic receptor activation. J Neural Transm Suppl. 2000;(60):227-45.

Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JP, Youdim MB. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm Suppl. 2000;(60):157-69.

Martin-Ruiz C, Court J, Lee M, Piggott M, Johnson M, Ballard C, Kalaria R, Perry R, Perry E. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand Suppl. 2000;176:34-41.

Zdrojewicz Z, Sowinska E. [The significance of galanin in physiologic and pathologic processes in humans] Postepy Hig Med Dosw. 2000;54(6):819-33.

Yamaji S, Ishii K, Sasaki M, Mori T, Kitagaki H, Sakamoto S, Mori E. Evaluation of standardized uptake value to assess cerebral glucose metabolism. Clin Nucl Med. 2000 Jan;25(1):11-6.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000 Jan;57(1):100-5. ,

Munoz DG, Ganapathy GR, Eliasziw M, Hachinski V. Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. Arch Neurol. 2000 Jan;57(1):85-9.

Farrer LA. Familial risk for Alzheimer disease in ethnic minorities: nondiscriminating genes. Arch Neurol. 2000 Jan;57(1):28-9.

Kurlan R, Richard IH, Papka M, Marshall F. Movement disorders in Alzheimer's disease: more rigidity of definitions is needed. Mov Disord. 2000 Jan;15(1):24-9.

Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000 Jan;66(1):196-204.

Finckh U, Müller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch RM, Gal A. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet. 2000 Jan;66(1):110-7.

Kazui H, Hashimoto M, Hirono N, Imamura T, Tanimukai S, Hanihara T, Ikeda M, Komori K, Ikejiri Y, Mori E. A study of remote memory impairment in Alzheimer's disease by using the family line test. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):53-8.

Lehtovirta M, Partanen J, Könönen M, Hiltunen J, Helisalmi S, Hartikainen P, Riekkinen P, Soininen H. A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):29-35.

Licastro F, Masliah E, Pedrini S, Thal LJ. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):25-8. ,

Monk D, Brodaty H. Use of estrogens for the prevention and treatment of Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):1-10.

Martin ER, Gilbert JR, Lai EH, Riley J, Rogala AR, Slotterbeck BD, Sipe CA, Grubber JM, Warren LL, Conneally PM, Saunders AM, Schmechel DE, Purvis I, Pericak-Vance MA, Roses AD, Vance JM. Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics. 2000 Jan 1;63(1):7-12.

Venneri A, Shanks MF, Staff RT, Della Sala S. Nurturing syndrome: a form of pathological bereavement with delusions in Alzheimer's disease. Neuropsychologia. 2000;38(2):213-24.

Galynker II, Dutta E, Vilkas N, Ongseng F, Finestone H, Gallagher R, Serseni D, Rosenthal RN. Hypofrontality and negative symptoms in patients with dementia of Alzheimer type. Neuropsychiatry Neuropsychol Behav Neurol. 2000 Jan;13(1):53-9.

Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl). 2000 Jan;99(1):14-20.

Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000 Jan;57(1):94-9.

Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem. 2000 Jan;74(1):270-9.

Hughes A, Coulter F, Gillespie R, Livingston H, Phillips K, Quinn E, Rimmer E, Smith M, Walker A. Anticholinesterases in the treatment of Alzheimer's dementia--the first year's experience in Argyll & Clyde. Health Bull (Edinb). 2000 Jan;58(1):20-4.

White H. Alzheimer's Disease Research in the Nursing Home Setting. J Am Med Dir Assoc. 2000 Jan-Feb;1(1):29-33.

Friedman G. The effects of estrogen on short-term memory in genetic men. J Am Med Dir Assoc. 2000 Jan-Feb;1(1):4-7.

Patel RN. Microbial/enzymatic synthesis of chiral drug intermediates. Adv Appl Microbiol. 2000;47:33-78.

Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy. Nucl Med Commun. 2000 Jan;21(1):37-41.

Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(2):CD001191.

Bobinski M, de Leon MJ, Wegiel J, DeSanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95(3):721-5.

Crowe SF, Hoogenraad K. Differentiation of dementia of the Alzheimer's type from depression with cognitive impairment on the basis of a cortical versus subcortical pattern of cognitive deficit. Arch Clin Neuropsychol. 2000 Jan;15(1):9-19.

Hinton L, Guo Z, Hillygus J, Levkoff S. Working with culture: a qualitative analysis of barriers to the recruitment of Chinese-American family caregivers for dementia research. J Cross Cult Gerontol. 2000;15(2):119-37.

Wada M. Olfactory evoked responses in Alzheimer's disease. Int Tinnitus J. 2000;6(2):160-3.

Blennow K, Ricksten A, Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Båtsman S, Marcusson J, Nägga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L, Rymo L. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm. 2000;107(8-9):1065-79. , ,

Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem. 2000 Jan;74(1):125-33.

Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000 Jan;156(1):139-50.

Rüther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000;107(7):815-29.

Sjögren M, Minthon L, Davidsson P, Granérus A-K , Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000;107(5):563-79. ,

Kunugi H, Akahane A, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S. No evidence for an association between the Glu298Asp polymorphism of the NOS3 gene and Alzheimer's disease. J Neural Transm. 2000;107(8-9):1081-4. ,

Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience. 2000;97(2):207-10.

Ihl R, Brinkmeyer J, Jänner M, Kerdar MS. A comparison of ADAS and EEG in the discrimination of patients with dementia of the Alzheimer type from healthy controls. Neuropsychobiology. 2000 Jan;41(2):102-7.

Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging. 2000 Jan-Feb;21(1):27-30. ,

Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin Genet. 2000 Jan;57(1):1-10.

McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJ, Faull RL, Snell RG. Amyloid-like inclusions in Huntington's disease. Neuroscience. 2000;100(4):677-80.

Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000 Jan-Feb;21(1):49-55.

Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 2000 Jan;20(1):1-12.

 

Guo ZH, Mattson MP. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex. 2000 Jan;10(1):50-7.

Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000 Jan;7(1):64-9.

Savaskan E, Müller-Spahn F, Olivieri G, Bruttel S, Otten U, Rosenberg C, Hulette C, Hock C. Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's disease. Eur Neurol. 2000;44(3):172-80.

Mastrianni JA, Roos RP. The prion diseases. Semin Neurol. 2000;20(3):337-52.

Lucock M, Daskalakis I. New perspectives on folate status: a differential role for the vitamin in cardiovascular disease, birth defects and other conditions. Br J Biomed Sci. 2000;57(3):254-60.

Palmer GC, Widzowski D. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids. 2000;19(1):151-5.

Ferrari E, Fioravanti M, Magri F, Solerte SB. Variability of interactions between neuroendocrine and immunological functions in physiological aging and dementia of the Alzheimer's type. Ann N Y Acad Sci. 2000;917:582-96.

Solerte SB, Cravello L, Ferrari E, Fioravanti M. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann N Y Acad Sci. 2000;917:331-40.

Gitter BD, Boggs LN, May PC, Czilli DL, Carlson CD. Regulation of cytokine secretion and amyloid precursor protein processing by proinflammatory amyloid beta (A beta). Ann N Y Acad Sci. 2000;917:154-64.

Wevers A, Witter B, Moser N, Burghaus L, Banerjee C, Steinlein OK, Schütz U, de Vos RA, Steur EN, Lindstrom J, Schröder H. Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? Acta Neurol Scand Suppl. 2000;176:42-8.

Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet. 2000 Jan 1;355(9197):42-3.

Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry. 2000 Jan;157(1):4-15.

Poser S, Zerr I, Schroeter A, Otto M, Giese A, Steinhoff BJ, Kretzschmar HA. Clinical and differential diagnosis of Creutzfeldt-Jakob disease. Arch Virol Suppl. 2000;(16):153-9.

Missiaen L, Callewaert G, Parys JB, Wuytack F, Raeymaekers L, Droogmans G, Nilius B, Eggermont J, De Smedt H. [Intracellular calcium: physiology and physiopathology] Verh K Acad Geneeskd Belg. 2000;62(6):471-99.

Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci. 2000;920:321-7.

Spangelo BL, Farrimond DD, Pompilius M, Bowman KL. Interleukin-1 beta and thymic peptide regulation of pituitary and glial cell cytokine expression and cellular proliferation. Ann N Y Acad Sci. 2000;917:597-607.

Soto C, Saborio GP, Permanne B. Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta Neurol Scand Suppl. 2000;176:90-5.

Chen JG, Charles HC, Barboriak DP, Doraiswamy PM. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand Suppl. 2000;176:20-6.

Cacabelos R, Alvarez A, Fenández-Novoa L, Lombardi VR. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand Suppl. 2000;176:12-9.

Wise PM. Estradiol: a protective factor in the adult brain. J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1425-9.

Berres M, Monsch AU, Bernasconi F, Thalmann B, Stähelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud Health Technol Inform. 2000;77:195-9.

Behl C. Apoptosis and Alzheimer's disease. J Neural Transm. 2000;107(11):1325-44.

Uchida Y, Ito S, Nukina N. Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms. J Clin Lab Anal. 2000;14(6):260-4.

Holden JE, Therrien B. The effect of familiarity on distraction and single cue use after hippocampal damage. Biol Res Nurs. 2000 Jan;1(3):165-78.

Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study. J Neural Transm. 2000;107(4):463-78.

Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm. 2000;107(10):1201-12.

Offen D, Elkon H, Melamed E. Apoptosis as a general cell death pathway in neurodegenerative diseases. J Neural Transm Suppl. 2000;(58):153-66.

Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience. 2000;101(4):939-44.

Gibbs RB. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. Neuroscience. 2000;101(4):931-8.

Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485-512.

Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol. 2000;14(4):406-8.

Goedert M, Ghetti B, Spillantini MG. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann N Y Acad Sci. 2000;920:74-83.

Earl-Slater A, Walley T. Donepezil and Alzheimer's dementia. Clin Perform Qual Health Care. 2000;8(1):47-51.

Kim KW, Jhoo JH, Lee KU, Lee DY, Lee JH, Youn JY, Lee BJ, Woo JI. No association between presenilin 1 (PS1) intronic polymorphism and sporadic Alzheimer's disease in Koreans. J Neural Transm. 2000;107(10):1191-200. ,

Suh YH, Kim HS, Lee JP, Park CH, Jeong SJ, Kim SS, Rah JC, Seo JH, Kim SS. Roles of A beta and carboxyl terminal peptide fragments of amyloid precursor protein in Alzheimer disease. J Neural Transm Suppl. 2000;(58):65-82.

McLean PJ, Ribich S, Hyman BT. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J Neural Transm Suppl. 2000;(58):53-63.

Rainer M, Kraxberger E, Haushofer M, Mucke HA, Jellinger KA. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm. 2000;107(12):1475-81.

Kvetnoy IM, Hernandez-Yago J, Kvetnaia TV, Khavinson VK, Malinin VV, Yarilin AA, Sharova NI, Blesa JR, Anisimov VN, Lenskaia LV, Sluchevskaia SF, Chekalina SI, Tokarev OY, Yuzhakov VV. Tau-protein expression in human blood lymphocytes: a promising marker and suitable sample for life-time diagnosis of Alzheimer's disease. Neuroendocrinol Lett. 2000;21(4):313-318.

Matsumoto E, Ohigashi Y, Fujimori M, Mori E. The processing of global and local visual information in Alzheimer's disease. Behav Neurol. 2000;12(3):119-25.

Bogdanovic N. Alzheimer's disease: plaques and tangles. J Cell Mol Med. 2000 Oct-Dec;4(4):304-305.

 

Popescu BO, Ankarcrona M. Neurons bearing presenilins: weapons for defense or suicide? J Cell Mol Med. 2000 Oct-Dec;4(4):249-261.

Bandorowicz-Pikula J. Lipid-binding proteins as stabilizers of membrane microdomains--possible physiological significance. Acta Biochim Pol. 2000;47(3):553-64.

Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl. 2000;176:60-7.

Aisen PS. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand Suppl. 2000;176:85-9.

Greig NH, De Micheli E, Holloway HW, Yu QS, Utsuki T, Perry TA, Brossi A, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl. 2000;176:74-84.

Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl. 2000;176:68-73.

Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV. Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl. 2000;176:53-9.

Sáez-Valero J, Mok SS, Small DH. An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. Acta Neurol Scand Suppl. 2000;176:49-52. ,

Sihver W, Långström B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl. 2000;176:27-33.

Carbonell T, Masip I, Sánchez-Baeza F, Delgado M, Araya E, Llorens O, Corcho F, Pérez JJ, Pérez-Payá E, Messeguer A. Identification of selective inhibitors of acetylcholinesterase from a combinatorial library of 2,5-piperazinediones. Mol Divers. 2000;5(3):131-43.

Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum Psychopharmacol. 2000 Jan;15(1):1-70.

Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 2000 Jan;59(1):11-7.

Nie W, Zhang YX. [Estrogen and Alzheimer's disease] Sheng Li Ke Xue Jin Zhan. 2000 Jan;31(1):65-8.

Colling KB. A taxonomy of passive behaviors in people with Alzheimer's disease. J Nurs Scholarsh. 2000;32(3):239-44.

Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):36-8.

Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):17-24.

Scherder EJ, Bouma A. Acute versus chronic pain experience in Alzheimer's disease. a new questionnaire. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):11-6.

Lezoualc'h F, Engert S, Berning B, Behl C. Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol. 2000 Jan;14(1):147-59.

Derouesné C, Lagha-Pierucci S, Thibault S, Baudouin-Madec V, Lacomblez L. Apraxic disturbances in patients with mild to moderate Alzheimer's disease. Neuropsychologia. 2000;38(13):1760-9.

LaBar KS, Mesulam M, Gitelman DR, Weintraub S. Emotional curiosity: modulation of visuospatial attention by arousal is preserved in aging and early-stage Alzheimer's disease. Neuropsychologia. 2000;38(13):1734-40.

Adamec E, Mohan PS, Cataldo AM, Vonsattel JP, Nixon RA. Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Neuroscience. 2000;100(3):663-75.

Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44(4):236-41.

Schachter AS, Davis KL. Alzheimer's Disease. Curr Treat Options Neurol. 2000 Jan;2(1):51-60.

Terry AV, Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neuroscience. 2000;101(2):357-68.

Morgan TE, Rozovsky I, Sarkar DK, Young-Chan CS, Nichols NR, Laping NJ, Finch CE. Transforming growth factor-beta1 induces transforming growth factor-beta1 and transforming growth factor-beta receptor messenger RNAs and reduces complement C1qB messenger RNA in rat brain microglia. Neuroscience. 2000;101(2):313-21.

Verfaellie M, Keane MM, Johnson G. Preserved priming in auditory perceptual identification in Alzheimer's disease. Neuropsychologia. 2000;38(12):1581-92.

Huber G, März W, Martin JR, Malherbe P, Richards JG, Sueoka N, Ohm T, Hoffmann MM. Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P; C112R). Neuroscience. 2000;101(1):211-8.

Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000;20(2):179-85.

Fujimori M, Imamura T, Hirono N, Ishii K, Sasaki M, Mori E. Disturbances of spatial vision and object vision correlate differently with regional cerebral glucose metabolism in Alzheimer's disease. Neuropsychologia. 2000;38(10):1356-61.

Moulin CJ, Perfect TJ, Jones RW. Evidence for intact memory monitoring in Alzheimer's disease: metamemory sensitivity at encoding. Neuropsychologia. 2000;38(9):1242-50.

Ehrenstein G, Galdzicki Z, Lange GD. A positive-feedback model for the loss of acetylcholine in Alzheimer's disease. Ann N Y Acad Sci. 2000;899:283-91.

Tringali G, Dello Russo C, Preziosi P, Navarra P. Interleukin-1 in the central nervous system: from physiology to pathology. Therapie. 2000 Jan-Feb;55(1):171-5.

Larousse C, Veyrac G. [Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?] Therapie. 2000 Jan-Feb;55(1):21-8.

Pekkonen E. Mismatch negativity in aging and in Alzheimer's and Parkinson's diseases. Audiol Neurootol. 2000 May-Aug;5(3-4):216-24.

Semenza C, Borgo F, Mondini S, Pasini M, Sgaramella T. Proper names in the early stages of Alzheimer's disease. Brain Cogn. 2000 Jun-Aug;43(1-3):384-7.

Roy E, Kalbfleisch L, Bryden P, Barbour K, Black S. Visual aiming movements in Alzheimer's disease. Brain Cogn. 2000 Jun-Aug;43(1-3):380-4.

Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn. 2000 Jun-Aug;43(1-3):274-82.

 

Hajilou BB, Done DJ, Gale TM. Investigating visual knowledge in dementia of the Alzheimer type (DAT): evidence for a structured organization. Brain Cogn. 2000 Jun-Aug;43(1-3):238-46.

Fung TD, Chertkow H, Templeman FD. Pattern of semantic memory impairment in dementia of Alzheimer's type. Brain Cogn. 2000 Jun-Aug;43(1-3):200-5.

Dumont C, Ska B. Pantomime recognition impairment in Alzheimer's disease. Brain Cogn. 2000 Jun-Aug;43(1-3):177-81.

Bara BG, Bucciarelli M, Geminiani GC. Development and decay of extra-linguistic communication. Brain Cogn. 2000 Jun-Aug;43(1-3):21-7.

Robertson TA, Dutton NS, Martins RN, Taddei K, Papadimitriou JM. Comparison of astrocytic and myocytic metabolic dysregulation in apolipoprotein E deficient and human apolipoprotein E transgenic mice. Neuroscience. 2000;98(2):353-9.

Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J Mol Neurosci. 2000 Feb-Apr;14(1-2):61-8.

Stoppe G, Bruhn H, Pouwels PJ, Hänicke W, Frahm J. Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis Assoc Disord. 2000 Apr-Jun;14(2):112-9.

Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord. 2000 Apr-Jun;14(2):102-11.

Vuorinen E, Laine M, Rinne J. Common pattern of language impairment in vascular dementia and in Alzheimer disease. Alzheimer Dis Assoc Disord. 2000 Apr-Jun;14(2):81-6.

Karlawish JH. Why we are not ready for a biopsychosocial approach to dementia research and intervention: commentary on "Heterogeneity in dementia: challenges and opportunities". Alzheimer Dis Assoc Disord. 2000 Apr-Jun;14(2):64-7.

Homma A. Current status of clinical trials for Alzheimer-type dementia in Japan: strategies to facilitate the development of antidementia drugs. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S123-6.

Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Tanada S, Irie T. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S114-8.

Jelic V, Nordberg A. Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S109-13.

Förstl H. Clinical issues in current drug therapy for dementia. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S103-8.

Nishizaki T, Matsuoka T, Nomura T, Kondoh T, Watabe S, Shiotani T, Yoshii M. Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S82-94.

de la Torre JC. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S72-81.

Takahashi M, Snyder SH. Interaction of amyloid precursor proteins and heme oxygenase. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S67-71.

Rottkamp CA, Nunomura A, Raina AK, Sayre LM, Perry G, Smith MA. Oxidative stress, antioxidants, and Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S62-6.

Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S54-61.

Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S47-53.

Nabeshima T, Yamada K. Neurotrophic factor strategies for the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S39-46.

Jönhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S31-8.

Tanaka T, Tsujio I, Nishikawa T, Shinosaki K, Kudo T, Takeda M. Significance of tau phosphorylation and protein kinase regulation in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S18-24.

Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S3-10.

Hooper NM, Trew AJ, Parkin ET, Turner AJ. The role of proteolysis in Alzheimer's disease. Adv Exp Med Biol. 2000;477:379-90.

Tyas SL, Koval JJ, Pederson LL. Does an interaction between smoking and drinking influence the risk of Alzheimer's disease? Results from three Canadian data sets. Stat Med. 2000 Jun 15-30;19(11-12):1685-96.

Milliken JK, Edland SD. Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. Stat Med. 2000 Jun 15-30;19(11-12):1617-29.

Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1607-16.

Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1555-66.

Gao S, Hui SL. Estimating the incidence of dementia from two-phase sampling with non-ignorable missing data. Stat Med. 2000 Jun 15-30;19(11-12):1545-54.

Foster NL, Gombosi E, Teboe C, Little RJ. Balanced centralized and distributed database design in a clinical research environment. Stat Med. 2000 Jun 15-30;19(11-12):1531-44.

Emsley CL, Gao S, Hall KS, Hendrie HC. Estimating odds ratios adjusting for misclassification in Alzheimer's disease risk factor assessment. Stat Med. 2000 Jun 15-30;19(11-12):1523-30.

Beiser A, D'Agostino RB, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med. 2000 Jun 15-30;19(11-12):1495-522.

Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1481-93.

Beckett LA. Community-based studies of Alzheimer's disease: statistical challenges in design and analysis. Stat Med. 2000 Jun 15-30;19(11-12):1469-80.

Schmitt FA, Miller JP, Kryscio RJ. Promoting interactions with basic scientists and clinicians: summary of the panel session. Stat Med. 2000 Jun 15-30;19(11-12):1463-8.

Cronin-Stubbs D, DeKosky ST, Morris JC, Evans DA. Promoting interactions with basic scientists and clinicians: the NIA Alzheimer's Disease Data Coordinating Center. Stat Med. 2000 Jun 15-30;19(11-12):1453-61.

Thomas RG, Berg JD, Sano M, Thal L. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med. 2000 Jun 15-30;19(11-12):1433-40.

Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1421-32.

van Belle G, Arnold A. Reliability of cognitive tests used in Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1411-20.

Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1401-9.

Gelb DJ. Measurement of progression in Alzheimer's disease: a clinician's perspective. Stat Med. 2000 Jun 15-30;19(11-12):1393-400.

Cambon K, Davies HA, Stewart MG. Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice. Neuroscience. 2000;97(4):685-92.

Bäckman L, Almkvist O, Nyberg L, Andersson J. Functional changes in brain activity during priming in Alzheimer's disease. J Cogn Neurosci. 2000 Jan;12(1):134-41.

Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI. Fatty acid mixture counters stress changes in cortisol, cholesterol, and impair learning. Int J Neurosci. 2000;101(1-4):73-87.

Fukuyama R, Mizuno T, Mori S, Yanagisawa K, Nakajima K, Fushiki S. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. Eur Neurol. 2000;43(3):161-9. ,

Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol. 2000;43(3):155-60. ,

Golbraikh A, Bernard P, Chrétien JR. Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models. Eur J Med Chem. 2000 Jan;35(1):123-36.

Carlson LE, Sherwin BB, Chertkow HM. Relationships between mood and estradiol (E2) levels in Alzheimer's disease (AD) patients. J Gerontol B Psychol Sci Soc Sci. 2000 Jan;55(1):P47-53.

Dodart JC, Mathis C, Ungerer A. The beta-amyloid precursor protein and its derivatives: from biology to learning and memory processes. Rev Neurosci. 2000;11(2-3):75-93.

Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord. 2000 Jan-Mar;14(1):39-45.

Perry RJ, Hodges JR. Relationship between functional and neuropsychological performance in early Alzheimer disease. Alzheimer Dis Assoc Disord. 2000 Jan-Mar;14(1):1-10.

Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000 Mar 22-29;283(12):1615-7.

    

Andreani A, Leoni A, Locatelli A, Morigi R, Rambaldi M, Pietra C, Villetti G. 4-Aminopyridine derivatives with antiamnesic activity. Eur J Med Chem. 2000 Jan;35(1):77-82.

Butterworth RF. Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol. 2000;32(1 Suppl):171-80.

Ownby RL, Harwood DG, Barker WW, Duara R. Predictors of anxiety in patients with Alzheimer's disease. Depress Anxiety. 2000;11(1):38-42.

Palacios S, Cifuentes I, Menendez C, von Helde S. The central nervous system and HRT. Int J Fertil Womens Med. 2000 Jan-Feb;45(1):13-21.

Kolasa K, Harrell LE, Parsons DS, Powers R. Densitometric analysis of Galphao protein subunit levels from postmortem Alzheimer disease hippocampal and prefrontal cortical membranes. Alzheimer Dis Assoc Disord. 2000 Jan-Mar;14(1):53-7.

Sommer B, Sturchler-Pierrat C, Abramowski D, Wiederhold KH, Calhoun M, Jucker M, Kelly P, Staufenbiel M. Transgenic approaches to model Alzheimer's disease. Rev Neurosci. 2000;11(1):47-51.

Jeong Lee H, Pardridge WM. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J Drug Target. 2000;8(6):413-24.

Deguchi Y, Hayashi H, Fujii S, Naito T, Yokoyama Y, Yamada S, Kimura R. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. J Drug Target. 2000;8(6):371-81.

Jiang S, Yu J, Wang J, Tan Z, Xue H, Feng G, He L, Yang H. Complete genomic sequence of 195 Kb of human DNA containing the gene GABRG2. DNA Seq. 2000;11(5):373-82.

Patrick RL. Synaptic clefts are made to be crossed: neurotransmitter signaling in the central nervous system. Toxicol Pathol. 2000 Jan-Feb;28(1):31-6.

Kim H, Xia H, Li L, Gewin J. Attenuation of neurodegeneration-relevant modifications of brain proteins by dietary soy. Biofactors. 2000;12(1-4):243-50.

Behl C. Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-beta estradiol and induces the activity of the transcription factor NF-kappaB. J Neural Transm. 2000;107(4):393-407.

Floyd RA, Hensley K, Bing G. Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics. J Neural Transm Suppl. 2000;(60):387-414.

Mössner R, Schmitt A, Syagailo Y, Gerlach M, Riederer P, Lesch KP. The serotonin transporter in Alzheimer's and Parkinson's disease. J Neural Transm Suppl. 2000;(60):345-50.

Jellinger KA, Stadelmann CH. The enigma of cell death in neurodegenerative disorders. J Neural Transm Suppl. 2000;(60):21-36.

Sapolsky RM, Finch CE. Alzheimer's disease and some speculations about the evolution of its modifiers. Ann N Y Acad Sci. 2000;924:99-103.

Green PS, Simpkins JW. Estrogens and estrogen-like non-feminizing compounds. Their role in the prevention and treatment of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:93-8.

Strittmatter WJ. Apolipoprotein E and Alzheimer's disease. Ann N Y Acad Sci. 2000;924:91-2.

Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci. 2000;924:81-90.

Davies P. A very incomplete comprehensive theory of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:8-16.

Kosik KS. The long reach of evolution and development. Effects on the Alzheimer brain. Ann N Y Acad Sci. 2000;924:76-80.

Masliah E. The role of synaptic proteins in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:68-75.

Trojanowski JQ, Lee VM. "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci. 2000;924:62-7.

Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci. 2000;924:53-61.

Mesulam MM. A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:42-52.

Ashe KH. Synaptic structure and function in transgenic APP mice. Ann N Y Acad Sci. 2000;924:39-41.

Smith MA, Joseph JA, Perry G. Arson. Tracking the culprit in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:35-8.

Hardy J. Pathways to primary neurodegenerative disease. Ann N Y Acad Sci. 2000;924:29-34.

Yankner BA. The pathogenesis of Alzheimer's disease. Is amyloid beta-protein the beginning or the end? Ann N Y Acad Sci. 2000;924:26-8.

Khachaturian ZS. Toward a comprehensive theory of Alzheimer's disease--challenges, caveats, and parameters. Ann N Y Acad Sci. 2000;924:184-93.

Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci. 2000;924:170-83.

Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17-25.

 

Beal MF. Oxidative metabolism. Ann N Y Acad Sci. 2000;924:164-9.

Carney JM. Oxidative stress leading to loss of critical proteases in Alzheimer's disease. An alternative view of the etiology of AD. Ann N Y Acad Sci. 2000;924:160-3.

Mattson MP. Existing data suggest that Alzheimer's disease is preventable. Ann N Y Acad Sci. 2000;924:153-9.

de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:136-52.

Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:132-5.

Nixon RA. A "protease activation cascade" in the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:117-31.

Cotman CW, Anderson AJ. The brain's microenvironment, early functional loss, and the conversion to Alzheimer's disease. Ann N Y Acad Sci. 2000;924:112-6.

Lynch C, Mobley W. Comprehensive theory of Alzheimer's disease. The effects of cholesterol on membrane receptor trafficking. Ann N Y Acad Sci. 2000;924:104-11.

St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:1-7.

Gómez-Tortosa E, Irizarry MC, Gómez-Isla T, Hyman BT. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann N Y Acad Sci. 2000;920:9-15.

Ghiso J, Vidal R, Rostagno A, Miravalle L, Holton JL, Mead S, Révész T, Plant G, Frangione B. Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. Ann N Y Acad Sci. 2000;920:84-92.

Hutton M. Molecular genetics of chromosome 17 tauopathies. Ann N Y Acad Sci. 2000;920:63-73.

Neary D, Snowden JS, Mann DM. Classification and description of frontotemporal dementias. Ann N Y Acad Sci. 2000;920:46-51.

Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann N Y Acad Sci. 2000;920:315-20.

Isacson O, Lin L. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease. Ann N Y Acad Sci. 2000;920:309-14.

Cuajungco MP, Fagét KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci. 2000;920:292-304.

Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci. 2000;920:285-91. ,

Lee RK, Wurtman RJ. Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann N Y Acad Sci. 2000;920:261-8.